Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 2:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 64 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: SLOW Carbohydrate Clear all
Completed Phase 1Phase 2 Interventional Results available

Metformin to Augment Low Milk Supply (MALMS) Study

NCT02179788
View directory record Official record
Conditions
Low Milk Supply, Pre-diabetes, Insulin Resistance, Suppressed Lactation
Interventions
Standard care, Metformin, Placebo
Behavioral · Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
20 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Sep 6, 2026, 2:24 AM EDT
Completed Phase 4 Interventional Results available

Adjunctive Topiramate for Treatment of Alcohol Dependence in Patients With Bipolar Disorder

NCT00572117
View directory record Official record
Conditions
Bipolar Disorder, Alcoholism, Alcohol Dependence
Interventions
Topiramate
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2017 · Synced Sep 6, 2026, 2:24 AM EDT
Recruiting Phase 2 Interventional

Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma

NCT05253495
View directory record Official record
Conditions
Non-hodgkin Lymphoma, Hodgkin Lymphoma
Interventions
DOC Group B, Pv-COMRAD 1 and 2 Group B, Pv-R-CYM 1 and 2 Group B, DOC Group C, MAD CPR 1 and 2, Pv-R CYVE 1 and 2, Pv-R CYVE-MTX 1 and 2, MAD CP, Pv-Cytarabine/etoposide, AD CP, Bv-AVD-R 1 and 2: COHORT IIa, Bv-NVD-R, Cycle 1-2, Bv-NVD-R, Cycle 1-4 SER, Bv-AVD-R, Bv-NVD-R, Cycle 1-4 RER, Bv-NAVD-R, Cycle 1-2, Involved Site Radiation Therapy
Drug · Radiation
Lead sponsor
New York Medical College
Other
Eligibility
3 Years to 39 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
3
States / cities
Birmingham, Alabama • Gainsville, Florida • Vallhala, New York
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Sep 6, 2026, 2:24 AM EDT
Completed Phase 2 Interventional

Phase 2 Study Comparing 99mTc-EC-DG SPECT/CT With 18F FDG PET/CT in Patients With Non-small Cell Lung Cancer (NSCLC)

NCT00865319
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose), 18 F fluorodeoxyglucose
Radiation
Lead sponsor
Cell>Point LLC
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
5
States / cities
Coral Gables, Florida • Decatur, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2013 · Synced Sep 6, 2026, 2:24 AM EDT
Completed Phase 1 Interventional

Pharmacokinetic and Radiation Dosimetry Study Evaluating 99m TC-EC-DG SPECT/CT in Patients With Non-small Cell Lung Cancer (NSCLC)

NCT00864110
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose), Technetium 99m ethylenedicysteine-deoxyglucose, 18 F fluorodeoxyglucose
Radiation
Lead sponsor
Cell>Point LLC
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
3
States / cities
Chicago, Illinois • Rochester, Minnesota • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 21, 2013 · Synced Sep 6, 2026, 2:24 AM EDT
Completed Phase 3 Interventional

Randomized Trial of a Nutritional Supplement in Alzheimer's Disease

NCT00678431
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Resveratrol with Glucose, and Malate, Placebo
Dietary Supplement
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
50 Years to 90 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 14, 2012 · Synced Sep 6, 2026, 2:24 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer

NCT00048893
View directory record Official record
Conditions
Breast Neoplasms, Metastases, Neoplasm
Interventions
recombinant fowlpox-CEA(6D)/TRICOM vaccine, recombinant vaccinia-CEA(6D)/TRICOM vaccine, filgrastim, sargramostim, cyclophosphamide, doxorubicin hydrochloride, fludarabine phosphate, paclitaxel, Mesna
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
2
States / cities
Bethesda, Maryland • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 12, 2012 · Synced Sep 6, 2026, 2:24 AM EDT
Active, not recruiting Phase 2 Interventional

Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer

NCT05090358
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Stage IV, Metastatic Breast Cancer
Interventions
Ketogenic Diet, Low Carbohydrate Diet, Alpelisib, Fulvestrant, Canagliflozin
Dietary Supplement · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
9
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 6, 2026, 2:24 AM EDT
Terminated Phase 2 Interventional Results available

Surgery and/or Chemotherapy in Treating Children With Infantile, Congenital, or Childhood Fibrosarcoma

NCT00072280
View directory record Official record
Conditions
Sarcoma
Interventions
dactinomycin, cyclophosphamide, etoposide, ifosfamide, vincristine sulfate, Conventional Surgery, MESNA (mercaptoethane sulfonate), Filgrastim
Biological · Drug · Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 2 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
64
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Downey, California + 57 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2014 · Synced Sep 6, 2026, 2:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Ability of a Tea Leaf Extracts Preparation to Slow Down Carbohydrate and Fat Absorption

NCT00262145
View directory record Official record
Conditions
Diabetes, Overweight
Interventions
tea extracts
Drug
Lead sponsor
NatureGen
Industry
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 5, 2005 · Synced Sep 6, 2026, 2:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Slowly Digestible Carbohydrates and the Ileal Brake

NCT03630445
View directory record Official record
Conditions
Obesity, Diabetes Mellitus, Type 2, Appetitive Behavior
Interventions
Isomaltooligosaccharides (IMOs), Xtend® sucromalt, Combination of IMOs and Xtend® sucromalt, Raw corn starch, Maltodextrin
Other
Lead sponsor
Purdue University
Other
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Sep 6, 2026, 2:24 AM EDT
Completed Phase 2 Interventional Results available

Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHL

NCT00732498
View directory record Official record
Conditions
Lymphoma
Interventions
Methylprednisolone, Etoposide, Cytarabine, Cisplatin, Rituximab, In-Zevalin, Y-Zevalin
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Sep 6, 2026, 2:24 AM EDT
Completed Phase 2 Interventional Results available

A Trial Comparing Ferumoxytol to Iron Sucrose for the Treatment of Iron Deficiency Anemia in Adult Subjects With Chronic Kidney Disease

NCT01052779
View directory record Official record
Conditions
Iron Deficiency, Anemia, Kidney Disease
Interventions
Ferumoxytol, Iron Sucrose
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
14
States / cities
Tempe, Arizona • Chula Vista, California • Mountain View, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Sep 6, 2026, 2:24 AM EDT
Completed Phase 1 Interventional

A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas

NCT02130869
View directory record Official record
Conditions
Neuroblastoma, Lymphoma, High-risk Tumor
Interventions
CD133+ selected autologous stem cell infusion, IL-2, hu14.18K322A, Busulfan, Melphalan, GM-CSF, Bendamustine, Etoposide, Cytarabine, Carboplatin, Haploidentical natural killer cell infusion, G-CSF, Etoposide phosphate, CliniMACS
Biological · Drug · Device
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 21, 2017 · Synced Sep 6, 2026, 2:24 AM EDT
Recruiting Phase 2 Interventional

Prophylactic Intravenous Calcium Gluconate to Decrease Blood Loss at Time of Cesarean Delivery in Pregnant Patients at High Risk for Uterine Atony

NCT07217899
View directory record Official record
Conditions
Blood Loss, Surgical, Blood Loss, Postoperative, Uterine Atony
Interventions
Calcium Gluconate, Saline
Drug · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 6, 2026, 2:24 AM EDT
Completed Not applicable Interventional Results available

Does Memantine Improve Verbal Memory Task Performance in Subjects With Partial Epilepsy and Memory Dysfunction?

NCT01054599
View directory record Official record
Conditions
Epilepsy
Interventions
Memantine, Sugar Pill
Drug · Other
Lead sponsor
American Academy of Neurology
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
3
States / cities
Atlanta, Georgia • Boston, Massachusetts • Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 10, 2017 · Synced Sep 6, 2026, 2:24 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) Attacks

NCT00168103
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
C1 Esterase Inhibitor, Placebo
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
6 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
17
States / cities
Granada Hills, California • Weston, Florida • Atlanta, Georgia + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2015 · Synced Sep 6, 2026, 2:24 AM EDT
Recruiting Not applicable Interventional

Ketogenic Diets for Weight Loss Maintenance: Impact on Energy Expenditure and Appetite in Individuals With Obesity

NCT06736028
View directory record Official record
Conditions
Obesity
Interventions
Diet Therapy, Calorie Restriction, Behavioral Support
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 6, 2026, 2:24 AM EDT
Completed Phase 3 Interventional Results available

Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction

NCT00433966
View directory record Official record
Conditions
Myocardial Infarction
Interventions
Bivalirudin, Unfractionated heparin, Bare metal stent, Paclitaxel-eluting stent
Drug · Device
Lead sponsor
Cardiovascular Research Foundation, New York
Other
Eligibility
18 Years and older
Enrollment
3,602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 3, 2017 · Synced Sep 6, 2026, 2:24 AM EDT
Completed Phase 2 Interventional Results available

A Randomized Trial of GM-CSF in Patients With ALI/ARDS

NCT00201409
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Placebo, GM-CSF
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 90 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
3
States / cities
Denver, Colorado • Atlanta, Georgia • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 28, 2015 · Synced Sep 6, 2026, 2:24 AM EDT
Completed Phase 4 Interventional Results available

Neuromuscular Blockade on Shoulder Pain of Elderly

NCT03210376
View directory record Official record
Conditions
Malignant Neoplasms of Digestive Organs, Malignant Neoplasms of Female Genital Organs, Malignant Neoplasms of Male Genital Organs, Malignant Neoplasms of Urinary Tract
Interventions
Deep Neuromuscular Blockade (NMB), Moderate Neuromuscular Blockade (NMB), Sugammadex, Neostigmine, Pain Assessment
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
65 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Sep 6, 2026, 2:24 AM EDT
Not listed Phase 1 Interventional

The Study of Biodistribution and Dosimetry of 99mTc-Glycopeptide(99mTc-GP) in Patients With Breast Cancer

NCT01159405
View directory record Official record
Conditions
Breast Cancer
Interventions
Radiolabeled (99mTc) GP (Glycopeptide)
Radiation
Lead sponsor
SeeCure LLC
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2014 · Synced Sep 6, 2026, 2:24 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The Efficacy and Tolerability of Acarbose in Healthy Individuals

NCT05542849
View directory record Official record
Conditions
Tolerance, Side Effect, Glucose Response
Interventions
Acarbose Tablets 50mg
Drug
Lead sponsor
AgelessRx
Industry
Eligibility
18 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 6, 2026, 2:24 AM EDT
Completed Not applicable Interventional Results available

The Effect of the Hyperinsulinemic Normoglycemic Clamp on Myocardial Function and Utilization of Glucose

NCT01187329
View directory record Official record
Conditions
Hyperglycemia, Aortic Valve Replacement, Aortic Stenosis, Cardiac Surgery
Interventions
hyperinsulinemic normoglycemic clamp (HNC), control group
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
40 Years to 84 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Sep 6, 2026, 2:24 AM EDT